CL2020002011A1 - Método para producir células asesinas naturales (nk) y composición para el tratamiento de cáncer - Google Patents

Método para producir células asesinas naturales (nk) y composición para el tratamiento de cáncer

Info

Publication number
CL2020002011A1
CL2020002011A1 CL2020002011A CL2020002011A CL2020002011A1 CL 2020002011 A1 CL2020002011 A1 CL 2020002011A1 CL 2020002011 A CL2020002011 A CL 2020002011A CL 2020002011 A CL2020002011 A CL 2020002011A CL 2020002011 A1 CL2020002011 A1 CL 2020002011A1
Authority
CL
Chile
Prior art keywords
cells
natural killer
composition
cancer treatment
producing natural
Prior art date
Application number
CL2020002011A
Other languages
English (en)
Spanish (es)
Inventor
Sang Woo Park
Yong Man Kim
Jae Seob Jung
Yong-Hee Rhee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190001981A external-priority patent/KR102732845B1/ko
Priority claimed from KR1020190001983A external-priority patent/KR102765799B1/ko
Application filed filed Critical
Publication of CL2020002011A1 publication Critical patent/CL2020002011A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2318—Interleukin-18 (IL-18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CL2020002011A 2018-02-01 2020-07-31 Método para producir células asesinas naturales (nk) y composición para el tratamiento de cáncer CL2020002011A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20180012938 2018-02-01
KR20180012942 2018-02-01
KR1020190001981A KR102732845B1 (ko) 2018-02-01 2019-01-07 자연살해세포의 생산방법
KR1020190001983A KR102765799B1 (ko) 2018-02-01 2019-01-07 Cd56+ 자연살해세포를 포함하는 항암용 조성물

Publications (1)

Publication Number Publication Date
CL2020002011A1 true CL2020002011A1 (es) 2021-02-12

Family

ID=68465207

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002011A CL2020002011A1 (es) 2018-02-01 2020-07-31 Método para producir células asesinas naturales (nk) y composición para el tratamiento de cáncer

Country Status (15)

Country Link
US (4) US10590385B2 (enExample)
EP (1) EP3746095A4 (enExample)
JP (3) JP7268039B2 (enExample)
CN (2) CN111757745B (enExample)
AU (2) AU2019215034C1 (enExample)
BR (1) BR112020015512A2 (enExample)
CA (1) CA3089853A1 (enExample)
CL (1) CL2020002011A1 (enExample)
IL (1) IL276365B2 (enExample)
MX (2) MX386373B (enExample)
MY (2) MY199514A (enExample)
NZ (1) NZ766453A (enExample)
PH (1) PH12020551151A1 (enExample)
SA (1) SA520412566B1 (enExample)
SG (1) SG11202007221QA (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101520534B1 (ko) * 2012-05-07 2015-05-21 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
KR102623244B1 (ko) 2016-12-21 2024-01-09 주식회사 엔케이맥스 면역 세포 및 포나티닙을 포함하는 약학 조성물 및 방법
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
EP4048296A4 (en) * 2019-11-29 2024-01-24 Nkmax Co., Ltd. METHOD FOR PRODUCING NATURAL KILLER CELLS AND COMPOSITIONS THEREOF
CN112626029B (zh) * 2020-12-22 2022-12-20 深圳市赛欧细胞技术有限公司 一种转基因修饰的Daudi细胞及其制备方法、应用
WO2022250312A1 (ko) * 2021-05-27 2022-12-01 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포
WO2024036226A1 (en) * 2022-08-10 2024-02-15 Nkmax Co., Ltd. Method of treating autism with expanded natural killer cells
CN117122612B (zh) * 2023-07-07 2024-08-27 河络新图生物科技(上海)有限公司 外周血单个核细胞在制备治疗/预防阿尔茨海默病的药物中的用途
CN116904397B (zh) * 2023-09-04 2023-12-26 山东德升细胞治疗工程技术有限公司 Nk细胞的细胞外囊泡的制备及应用

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1320906C (en) 1986-06-04 1993-08-03 Daniel R. Twardzik Interleukin-2 induced antineoplastic peptide
JPH04503607A (ja) 1989-02-24 1992-07-02 イムノセラピューティックス・インコーポレイテッド 固定化サイトカイン類
GR1001034B (el) 1989-07-21 1993-03-31 Ortho Pharma Corp Μεθοδος διεγερσης του πολλαπλασιασμου λεμφοκυτταρων περιφερειακου αιματος.
US5415874A (en) 1989-10-31 1995-05-16 The Board Of Trustees Of The Leland Stanford Junior University Natural killer cell lines and clones with antigen specificity
US6194204B1 (en) 1996-08-02 2001-02-27 Center For Blood Research, Inc. Enrichment of dendritic cells from blood
DE19813759C1 (de) 1998-03-27 1999-07-15 Gsf Forschungszentrum Umwelt Verfahren zur Induktion einer durch NK-Zellen vermittelten Immunantwort
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
JP2004527263A (ja) 2001-05-30 2004-09-09 フォンダツィオーネ テレソン 免疫抑制活性を有するエクスビボ単離ｃｄ２５＋ｃｄ４＋ｔ細胞とその使用
US20030068306A1 (en) 2001-09-14 2003-04-10 Dilber Mehmet Sirac Medium
US7544355B2 (en) 2002-03-13 2009-06-09 Universita Degli Studi Di Perugia Methods and compositions for allogeneic transplantation
EP2377547A1 (en) 2002-06-07 2011-10-19 ZymoGenetics, Inc. Use of IL-21 as an antimicrobial agent
WO2004009021A2 (en) 2002-07-18 2004-01-29 University Of Washington Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same
US20050191743A1 (en) 2002-10-03 2005-09-01 Wu J.H. D. Three-dimensional peripheral lymphoid organ cell cultures
JP4033390B2 (ja) 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
WO2006004592A2 (en) 2004-05-28 2006-01-12 Mayo Foundation For Medical Education And Research Methods for autologous stem cell transplantation
US20090104170A1 (en) 2004-11-02 2009-04-23 Richard William Wyatt Childs Compositions and methods for treating hyperproliferative disorders
AU2005309502B2 (en) 2004-11-24 2011-11-17 Hill's Pet Nutrition, Inc. Methods for increasing the immune response in an animal
EP1863905B1 (en) 2005-03-17 2016-01-20 UCL Business PLC Method for activating natural killer cells by tumour cell preparations in vitro
EP1739166B1 (en) 2005-07-01 2011-06-22 TxCell S.A. Obtention of food- or auto-antigen specific Tr1 cells from a leukocyte or PBMC population
US9121008B2 (en) 2005-08-31 2015-09-01 University Of Utah Research Foundation Development of natural killer cells and functional natural killer cell lines
EP1941027B1 (en) 2005-09-28 2014-08-20 IPD-Therapeutics B.V. Methods and means for stem cell proliferation and subsequent generation and expansion of progenitor cells, as well as production of effector cells as clinical therapeutics.
CA2645042A1 (en) 2006-03-06 2007-09-13 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer
WO2008118369A2 (en) 2007-03-22 2008-10-02 Dendreon Corporation Methods for inducing a natural killer (nk) cell-mediated immune response and for increasing nk cell activity
CA2682243C (en) 2007-03-27 2019-07-23 Ipd-Therapeutics B.V. Methods and means for stem cell proliferation and subsequent generation and expansion of progenitor cells, as well as production of effector cells as clinical therapeutics
KR100902340B1 (ko) 2007-08-02 2009-06-12 한국생명공학연구원 Ｙｃ－１ 또는 ｉｌ－２１을 유효성분으로 포함하는자연살해세포 분화제 및 분화 방법
DK2520643T3 (da) 2007-12-07 2020-01-20 Miltenyi Biotec Bv & Co Kg Prøvebehandlingssystemer og -fremgangsmåder
KR101133185B1 (ko) 2008-07-29 2012-04-06 서울대학교병원 자연살해세포의 증식방법
KR101077912B1 (ko) * 2008-10-24 2011-10-31 주식회사 메디셀 제대혈로부터 효율적인 자연살해세포의 증식 및 분화 방법
KR101720961B1 (ko) 2009-02-27 2017-03-29 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 다능성 세포의 분화
ES2763169T3 (es) 2009-03-26 2020-05-27 Cellprotect Nordic Pharmaceuticals Ab Expansión de células NK
TW201127959A (en) 2010-02-12 2011-08-16 Ivy Life Sciences Co Ltd Method of producing immune killer cell
US20130059379A1 (en) 2010-02-24 2013-03-07 Ingo Schmidt-Wolf Method for the generation of a cik cell and nk cell population
JP5996533B2 (ja) 2010-07-13 2016-09-21 アントフロゲネシス コーポレーション ナチュラルキラー細胞を生成させる方法
KR101145391B1 (ko) 2010-08-16 2012-05-15 고려대학교 산학협력단 말초혈액으로부터 자연 살해세포의 증식 방법
TWI439275B (zh) 2010-12-31 2014-06-01 Glory Biomedical Co Ltd 一種人類自然殺手細胞之體外增殖方法
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
CA2830080C (en) 2011-03-18 2021-10-26 Jan Spanholtz Generation of nk cells and nk-cell progenitors
JP5572863B2 (ja) 2011-06-24 2014-08-20 国立大学法人九州大学 Ｎｋ細胞の増幅方法
JP6010136B2 (ja) 2011-12-22 2016-10-19 モガム バイオテクノロジー インスティチュート ナチュラルキラー細胞の製造方法、その方法により製造されたナチュラルキラー細胞、並びにそれを含む腫瘍及び感染性疾患治療用組成物
US20150010583A1 (en) 2012-02-08 2015-01-08 Ipd-Therapeutics B.V. Ex vivo nk cell differentiation from cd34+ hematopoietic cells
JP6339998B2 (ja) 2012-04-24 2018-06-06 ダン エス． カウフマン， 幹細胞よりナチュラルキラー細胞を発生させる方法
KR101520534B1 (ko) 2012-05-07 2015-05-21 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
DK3578201T3 (da) 2012-06-28 2023-05-08 Univ Of Central Florida Research Foundation Incorporated Fremgangsmåder og sammensætninger til naturlige dræberceller
US9175266B2 (en) * 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
JP5856025B2 (ja) 2012-08-02 2016-02-09 阿部　博幸 単球またはｎｋ細胞を入手する方法
CN102988415B (zh) 2012-08-15 2014-11-19 中航（宁夏）生物有限责任公司 人异基因有核细胞工业化制备自然杀伤性细胞(nk)及注射液
WO2014079946A1 (en) 2012-11-21 2014-05-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining the risk of acute graft versus host disease
CN104919042A (zh) 2013-01-15 2015-09-16 阿部博幸 含免疫细胞组合物的制造方法及癌治疗用组合物
CN115137753A (zh) * 2013-02-05 2022-10-04 细胞结构公司 来自胎盘的自然杀伤细胞
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
EP4032540A1 (en) 2013-04-19 2022-07-27 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
SG11201602979RA (en) 2013-10-17 2016-05-30 Univ Singapore Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
CA2935459C (en) 2014-01-03 2021-04-27 FullHope Biomedical Co., Ltd. Modified natural killer cells, compositions and uses thereof
WO2015125113A1 (en) 2014-02-21 2015-08-27 Dr. Reddy's Laboratories Limited Method of culturing high cell density pbmc's
ES2880718T3 (es) * 2014-03-07 2021-11-25 Emercell Sas Células NK de sangre del cordón umbilical combinadas y sus usos para el tratamiento del cáncer y enfermedades infecciosas crónicas
WO2015154012A1 (en) 2014-04-03 2015-10-08 Memorial Sloan-Kettering Cancer Center Clonogenic natural killer (nk) cell populations and methods of producing and using such populations
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
EP3838288A1 (en) 2014-06-11 2021-06-23 polybiocept GmbH Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
JP2016008198A (ja) 2014-06-24 2016-01-18 国立大学法人名古屋大学 間質性膀胱炎の治療
CN106687581A (zh) 2014-07-07 2017-05-17 塔尔加泽梅股份有限公司 用于治疗用途的岩藻糖基化细胞的制备和冷冻干燥
JP2016077185A (ja) 2014-10-14 2016-05-16 学校法人 聖マリアンナ医科大学 γδＴ細胞の製造方法および医薬
SMT202100055T1 (it) 2014-11-19 2021-03-15 Axon Neuroscience Se Anticorpi tau umanizzati nella malattia di alzheimer
EP3034092A1 (en) 2014-12-17 2016-06-22 Université de Lausanne Adoptive immunotherapy for treating cancer
CA2972806A1 (en) 2014-12-31 2016-07-07 Anthrogenesis Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
WO2016122014A1 (ko) 2015-01-27 2016-08-04 한국생명공학연구원 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 항암제로서의 용도
CN104705291A (zh) 2015-04-03 2015-06-17 广州赛莱拉干细胞科技股份有限公司 一种脐血单个核细胞冻存液、应用、制备方法
GB201509202D0 (en) 2015-05-28 2015-07-15 Ge Healthcare Bio Sciences Ab Semi-static cell culture
WO2016209021A1 (ko) 2015-06-24 2016-12-29 주식회사 차바이오텍 자연살해세포의 증식 방법 및 자연살해세포 증식용 조성물
KR101851270B1 (ko) 2015-07-10 2018-04-25 고려대학교 산학협력단 자연 살해세포의 대량증식 방법 및 배양용 조성물
EP3138905A1 (en) * 2015-09-04 2017-03-08 Miltenyi Biotec GmbH Method for natural killer cell expansion
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
CN105524880A (zh) 2016-01-27 2016-04-27 上海润泉生物技术有限公司 一种免疫细胞库的构建方法
CN107267454B (zh) 2016-04-07 2025-05-23 内蒙古原生元生物科技有限公司 一种脐血nk细胞的体外扩增方法及其试剂盒与应用
KR101968184B1 (ko) * 2016-04-29 2019-04-15 고려대학교 산학협력단 저산소 조건을 이용한 면역세포의 증식 배양 방법
WO2017196657A1 (en) * 2016-05-07 2017-11-16 Anthrogenesis Corporation Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
EP3487991B1 (en) 2016-07-25 2022-09-07 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of producing modified natural killer cells and methods of use
CA3039532A1 (en) 2016-10-05 2018-04-12 University Of Central Florida Research Foundation, Inc. Methods and compositions related to nk cell and anti-pdl1 cancer therapies
US10300089B2 (en) 2016-11-08 2019-05-28 University Of Central Florida Research Foundation, Inc. Methods for high scale therapeutic production of memory NK cells
KR102623244B1 (ko) 2016-12-21 2024-01-09 주식회사 엔케이맥스 면역 세포 및 포나티닙을 포함하는 약학 조성물 및 방법
WO2018161026A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il15 compositions and methods for immunotherapy
KR101948534B1 (ko) 2017-04-20 2019-02-15 주식회사 이뮤니스바이오 세포밀도 조절을 이용한 자연살해세포의 대량증식방법
AU2018271755B2 (en) 2017-05-26 2021-12-23 Green Cross Lab Cell Corporation Method for culturing natural killer cell, using transformed T cell
WO2019014684A1 (en) 2017-07-14 2019-01-17 Ohio State Innovation Foundation EXPANSION OF IMMUNE CELLS WITH INTERLEUKIN-INDUCIBLE T CELL KINASE-INHIBITING COMPOUNDS
SG11202000939PA (en) 2017-08-03 2020-02-27 Synthorx Inc Cytokine conjugates for the treatment of proliferative and infectious diseases
US20210128567A1 (en) 2017-08-29 2021-05-06 Flaask, Llc Compositions and Methods for Cognitive, Immune and Digestive Support in Patients with Autism Spectrum Disorder
CN107970258B (zh) 2017-11-20 2020-11-10 英普乐孚生物技术(上海)有限公司 一种嵌合抗原受体t细胞制剂
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
KR102765799B1 (ko) 2018-02-01 2025-02-13 주식회사 엔케이맥스 Cd56+ 자연살해세포를 포함하는 항암용 조성물
KR102732845B1 (ko) 2018-02-01 2024-11-25 주식회사 엔케이맥스 자연살해세포의 생산방법
WO2019152663A1 (en) 2018-02-01 2019-08-08 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
BR112020016876A2 (pt) 2018-02-21 2020-12-15 Board Of Regents, The University Of Texas System Células apresentadoras de antígeno universal e usos das mesmas
WO2019168222A1 (ko) 2018-02-28 2019-09-06 주식회사 제넨셀 말초혈액단핵구 유래 항암 활성화 림프구 배양용 배지 조성물 및 이를 이용한 항암 활성화 림프구 배양방법
ES2973728T3 (es) 2018-03-13 2024-06-24 Fundacion Para La Investigacion Biomedica Del Hospital Univ La Paz Anticuerpo anti-CXCR4 combinado con linfocitos citolíticos naturales activados y expandidos para inmunoterapia contra el cáncer
EP3539552A1 (en) 2018-03-16 2019-09-18 Deutsches Rheuma-Forschungszentrum Berlin Activation and expansion of nkg2c+ nk cells
WO2019182392A1 (ko) 2018-03-23 2019-09-26 주식회사 녹십자랩셀 자연살해세포의 제조방법
SG11202010763VA (en) 2018-05-03 2020-11-27 Univ Texas Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
WO2019229109A1 (en) 2018-05-30 2019-12-05 Glycostem Therapeutics B.V. Car nk cells
WO2020006139A1 (en) 2018-06-27 2020-01-02 The George Washington University Targeting stat sumoylation to enhance immune responses
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CN109294985B (zh) 2018-10-25 2022-02-18 江苏普瑞康生物医药科技有限公司 一种用于nk细胞体外扩增的培养基体系及nk细胞体外扩增的方法
BR112021008461A2 (pt) 2018-11-08 2021-08-03 Gammadelta Therapeutics Ltd métodos para isolamento e expansão de células
WO2020101361A1 (ko) 2018-11-14 2020-05-22 주식회사 녹십자랩셀 형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법
CN111205361B (zh) 2018-11-22 2022-05-06 海珂分子（北京）科技有限责任公司 白介素21蛋白(il21)突变体及其应用
EP3656851A1 (en) 2018-11-23 2020-05-27 Technische Universität Dresden Artificial hla-positive feeder cell lines for nk cells and uses thereof
EP3886877A4 (en) 2018-11-26 2022-08-24 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
WO2020112493A1 (en) 2018-11-29 2020-06-04 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
CA3125529A1 (en) 2019-01-07 2020-07-16 Inhibrx, Inc. Polypeptides comprising modified il-2 polypeptides and uses thereof
WO2020172328A1 (en) 2019-02-20 2020-08-27 Rutgers, The State University Of New Jersey Expansion of natural killer and chimeric antigen receptor-modified cells
CU24712B1 (es) 2019-03-15 2024-07-10 Centre Hospitalier Univ Vaudois Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva
KR20220004992A (ko) 2019-03-29 2022-01-12 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Car-nk 세포의 생산 방법 및 이의 용도
CN114173794A (zh) 2019-06-25 2022-03-11 希望之城 Pdl1阳性nk细胞癌症治疗
EP4048296A4 (en) 2019-11-29 2024-01-24 Nkmax Co., Ltd. METHOD FOR PRODUCING NATURAL KILLER CELLS AND COMPOSITIONS THEREOF
US20250195574A1 (en) 2022-06-02 2025-06-19 Nkmax Co., Ltd. Method for reduction of immune checkpoint therapy related adverse events
US20250255903A1 (en) 2022-07-12 2025-08-14 Nkmax Co., Ltd. Method of treating parkinson's disease with expanded natural killer cells
WO2024036005A1 (en) 2022-08-10 2024-02-15 Nkmax Co., Ltd. Method of treating alzheimer's disease with expanded natural killer cells
WO2024036226A1 (en) 2022-08-10 2024-02-15 Nkmax Co., Ltd. Method of treating autism with expanded natural killer cells

Also Published As

Publication number Publication date
US20250059510A1 (en) 2025-02-20
US10590385B2 (en) 2020-03-17
CN111757745B (zh) 2022-11-04
CA3089853A1 (en) 2019-08-08
JP2023153361A (ja) 2023-10-17
BR112020015512A2 (pt) 2021-01-26
US20190345449A1 (en) 2019-11-14
JP2022000060A (ja) 2022-01-04
AU2021266198B2 (en) 2024-12-19
IL276365B2 (en) 2023-10-01
SA520412566B1 (ar) 2025-05-11
EP3746095A4 (en) 2021-04-21
RU2020128764A (ru) 2022-03-01
MX2020008039A (es) 2021-09-20
US20200172869A1 (en) 2020-06-04
MX386373B (es) 2025-03-18
MY199514A (en) 2023-11-02
MY197176A (en) 2023-05-30
JP7268039B2 (ja) 2023-05-02
CN111757745A (zh) 2020-10-09
JP7339309B2 (ja) 2023-09-05
RU2020128764A3 (enExample) 2022-03-01
MX2021004682A (es) 2021-06-04
AU2019215034B2 (en) 2021-08-19
IL276365B1 (en) 2023-06-01
NZ766453A (en) 2022-02-25
AU2019215034C1 (en) 2022-01-06
CN115710576A (zh) 2023-02-24
AU2021266198A1 (en) 2021-12-02
US11066644B2 (en) 2021-07-20
US12098388B2 (en) 2024-09-24
EP3746095A1 (en) 2020-12-09
SG11202007221QA (en) 2020-08-28
JP2021506333A (ja) 2021-02-22
IL276365A (en) 2020-09-30
JP7669434B2 (ja) 2025-04-28
AU2019215034A1 (en) 2020-08-27
US20210032597A1 (en) 2021-02-04
PH12020551151A1 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
CL2020002011A1 (es) Método para producir células asesinas naturales (nk) y composición para el tratamiento de cáncer
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
CO2021000151A2 (es) Inhibidores de pd-1/pd-l1
CL2021000293A1 (es) Anticuerpos anti-trem2 y métodos relacionados (divisional de solicitud no.202001575)
CO2020004906A2 (es) Composiciones y métodos para la eliminación de células cd117+
CL2020003422A1 (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CO2021006259A2 (es) Conjugados de anticuerpos y fármacos (caf) con silenciamiento de fc y usos de los mismos
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
MX2022009596A (es) Anticuerpos anti-ror1 y composiciones.
MX2021013368A (es) Celulas t del receptor de antigenos quimericos focalizadas a cd19 especificas del antigeno.
CO2022000402A2 (es) Uso de linfocitos t con receptor de antígeno quimérico e inhibidores de linfocitos citolíticos naturales para el tratamiento del cáncer
MX2022005249A (es) Anticuerpos anti-cd45 y conjugados de los mismos.
ECSP20082339A (es) Moduladores de la expresión de apol1
BR112021024822A2 (pt) Terapia de combinação de terapia citotóxica mediada por células e inibidor de proteína da família bcl2 pró-sobrevivência
Amatangelo et al. Iberdomide (CC-220) has synergistic anti-tumor and immunostimulatory activity against multiple myeloma in combination with both bortezomib and dexamethasone, or in combination with daratumumab in vitro
MX2019005661A (es) Método para tratar la psoriasis con el anticuerpo específico anti-il23.
CL2023003841A1 (es) Trampas de ligando del factor de crecimiento transformante beta para el tratamiento de enfermedades
CO2021014747A2 (es) Métodos para el tratamiento de βeta-talasemia
CO2021007006A2 (es) Moduladores de la expresión de irf5
MX2019008460A (es) Metodos para tratar esclerosis multiple usando celulas t autologas.
CO2017010151A2 (es) Material de implante compuesto
MX2023015070A (es) Anticuerpo anti-cd40, fragmento de union a antigeno y uso medico del mismo.
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
CL2024002103A1 (es) Métodos para tratar amiloidosis al